Axumin
Total Payments
$13.2M
Transactions
20,191
Doctors
6,712
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $900,286 | 129 | 5 |
| 2023 | $636,546 | 1,610 | 1,134 |
| 2022 | $2.7M | 3,935 | 2,187 |
| 2021 | $3.1M | 4,998 | 2,741 |
| 2020 | $1.1M | 1,454 | 858 |
| 2019 | $1.5M | 3,703 | 2,098 |
| 2018 | $1.4M | 2,589 | 1,641 |
| 2017 | $1.8M | 1,773 | 1,158 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.9M | 1,332 | 83.1% |
| Consulting Fee | $1.4M | 369 | 10.5% |
| Food and Beverage | $451,783 | 18,008 | 3.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $186,728 | 103 | 1.4% |
| Travel and Lodging | $96,093 | 139 | 0.7% |
| Honoraria | $56,163 | 48 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $27,900 | 13 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $18,550 | 20 | 0.1% |
| Education | $5,579 | 158 | 0.0% |
| Grant | $1,200 | 1 | 0.0% |
Payments by Type
Research
$10.9M
1,332 transactions
General
$2.2M
18,859 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| The Impact of 18F Fluciclovine FACBC PETCT Positron Emission Computed Tomography on Management of Patients With Rising PSA Prostate-specific Antigen After Initial Prostate Cancer Treatment | Blue Earth Diagnostics Limited | $1.6M | 0 |
| An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy | Blue Earth Diagnostics Limited | $1.5M | 0 |
| An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy (the Protocol). | Blue Earth Diagnostics Limited | $1.3M | 0 |
| Retrospective Observational Study Investigating Fluciclovine 18F FACBC | Blue Earth Diagnostics Limited | $501,304 | 0 |
| An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy | Blue Earth Diagnostics Limited | $452,534 | 0 |
| Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET | Blue Earth Diagnostics Limited | $377,337 | 0 |
| An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy as it is amended time to time and approved by the IRB (the Protocol) | Blue Earth Diagnostics Limited | $306,499 | 0 |
| Utility of FDG-PET Scanning in Prostate Cancer Patients with Biochemical Recurrence | Blue Earth Diagnostics Limited | $282,500 | 0 |
| PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy | Blue Earth Diagnostics Limited | $255,184 | 0 |
| To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression vs pseudoprogression. To determine a multidimensional signature using 18F-fluciclovine PET, MRI, and plasma cfDNA that accurately differentiates tumor progression from pseudoprogression in post-chemoradiation GBM. | Blue Earth Diagnostics Limited | $238,657 | 0 |
| Prospective Comparison of Pelvic CT or MRI Plus Bone Scanning With 99mTc-MDP Bone Scan and/or 18F-NaF PET/CT to 18F- Fluciclovine PET/CT in VA Prostate Cancer Patients With BCR. | Blue Earth Diagnostics Limited | $196,875 | 0 |
| Prospective Comparison of Pelvic CT or MRI Plus Bone Scanning With 99mTc-MDP Bone Scan andor 18F-NaF PETCT to 18F- Fluciclovine PETCT in VA Prostate Cancer Patients With BCR. | Blue Earth Diagnostics Limited | $174,180 | 0 |
| Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy | Blue Earth Diagnostics Limited | $162,905 | 0 |
| CLINICAL UTILITY OFAXUMINPET/MRI IMAGING TWO YEARS FOLLOWINGFOCAL CRYO-ABLATION(FCA) OF PROSTATE CANCER | Blue Earth Diagnostics Limited | $161,470 | 0 |
| Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. | Blue Earth Diagnostics Limited | $144,800 | 0 |
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis | Blue Earth Diagnostics Limited | $142,861 | 0 |
| Fluciclovine(FACBC)PET/CT Site-Directed TherapyforTreatmentofProstate Cancer | Blue Earth Diagnostics Limited | $133,333 | 0 |
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis (CONCORDANT) | Blue Earth Diagnostics Limited | $127,500 | 0 |
| Characterization of Large Brain Metastases with 18F-Fluciclovine PET/CT Treated with Staged Stereotactic Radiosurgery | Blue Earth Diagnostics Limited | $123,564 | 0 |
| Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PETMRI | Blue Earth Diagnostics Limited | $114,255 | 0 |
Top Doctors Receiving Payments for Axumin — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Medical Oncology | New York, NY | $6,594 | 5 |
| , MD | Nuclear Radiology | Saint Louis, MO | $6,399 | 8 |
| , MD | Nuclear Radiology | Philadelphia, PA | $6,031 | 5 |
| , MD | Neurology | Boston, MA | $5,775 | 3 |
| Felix Feng | — | Ann Arbor, MI | $5,706 | 6 |
| , M.D | Urology | Worcester, MA | $5,369 | 16 |
| , M.D | Specialist | Philadelphia, PA | $4,911 | 5 |
| , MD | Nuclear Medicine | Fort Myers, FL | $4,817 | 12 |
| , M.D., PH.D | Anatomic Pathology | Boston, MA | $4,800 | 5 |
| , MD | Internal Medicine | Los Angeles, CA | $4,746 | 10 |
| , M.D | Diagnostic Radiology | Los Angeles, CA | $4,723 | 7 |
| , MD | Urology | Jacksonville, FL | $4,717 | 13 |
| , MD | Urology | Bellaire, TX | $4,653 | 9 |
| , M.D | Neurological Surgery | New Orleans, LA | $4,429 | 4 |
| , M.D | Nuclear Radiology | New York, NY | $4,422 | 6 |
| , MD, PHD, MPH | Nuclear Radiology | Dallas, TX | $4,281 | 7 |
| , MD | Diagnostic Radiology | Scottsdale, AZ | $4,222 | 8 |
| , MD | Diagnostic Radiology | Philadelphia, PA | $4,185 | 6 |
| , MD, PHD | Diagnostic Radiology | Rochester, MN | $4,125 | 2 |
| Daniel Appelbaum | Nuclear Radiology | Chicago, IL | $4,100 | 2 |
| , MD | Radiation Oncology | Miami, FL | $4,038 | 2 |
| , M.D | Medical Oncology | New Orleans, LA | $4,009 | 5 |
| , MD | Family Medicine | Madison, WI | $3,964 | 3 |
| , MD PHD | Neurology | Boston, MA | $3,958 | 3 |
| , MD | Radiation Oncology | Boston, MA | $3,838 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $13.2M
- Total Doctors 6,712
- Transactions 20,191
About Axumin
Axumin is a device associated with $13.2M in payments to 6,712 healthcare providers, recorded across 20,191 transactions in the CMS Open Payments database. The primary manufacturer is Blue Earth Diagnostics Limited.
Payment data is available from 2017 to 2024. In 2024, $900,286 was paid across 129 transactions to 5 doctors.
The most common payment nature for Axumin is "Unspecified" ($10.9M, 83.1% of total).
Axumin is associated with 20 research studies, including "The Impact of 18F Fluciclovine FACBC PETCT Positron Emission Computed Tomography on Management of Patients With Rising PSA Prostate-specific Antigen After Initial Prostate Cancer Treatment" ($1.6M).